Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price reached a new 52-week high during trading on Friday . The company traded as high as $6.04 and last traded at $5.68, with a volume of 53291 shares. The stock had previously closed at $5.87.
ADAP has been the subject of several analyst reports. Mizuho started coverage on Adaptimmune Therapeutics in a report on Tuesday, April 21st. They issued a “neutral” rating and a $3.00 price objective for the company. Citigroup decreased their price target on Adaptimmune Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, April 27th. SVB Leerink reissued a “market perform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, May 14th. BidaskClub raised shares of Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Adaptimmune Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $5.19.
The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.64 and a current ratio of 7.64. The company has a 50 day moving average price of $3.69 and a 200 day moving average price of $2.73.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. Adaptimmune Therapeutics had a negative return on equity of 85.62% and a negative net margin of 7,324.48%. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $25.90 million. On average, research analysts anticipate that Adaptimmune Therapeutics PLC – will post -1.02 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Matrix Capital Management Company LP raised its holdings in Adaptimmune Therapeutics by 23.0% in the 1st quarter. Matrix Capital Management Company LP now owns 34,428,730 shares of the biotechnology company’s stock valued at $93,646,000 after acquiring an additional 6,428,730 shares during the period. NEA Management Company LLC grew its position in shares of Adaptimmune Therapeutics by 7.9% in the first quarter. NEA Management Company LLC now owns 17,082,611 shares of the biotechnology company’s stock valued at $46,465,000 after purchasing an additional 1,250,000 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Adaptimmune Therapeutics during the first quarter worth approximately $34,114,000. Capital World Investors lifted its holdings in Adaptimmune Therapeutics by 17.8% during the 1st quarter. Capital World Investors now owns 8,002,700 shares of the biotechnology company’s stock worth $21,767,000 after purchasing an additional 1,210,000 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in Adaptimmune Therapeutics by 1.6% during the 1st quarter. Baillie Gifford & Co. now owns 4,354,023 shares of the biotechnology company’s stock worth $11,843,000 after purchasing an additional 66,478 shares during the last quarter. Institutional investors and hedge funds own 50.59% of the company’s stock.
About Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Recommended Story: Inverted Yield Curve
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.